Formycon AG
XETRA:FYB
Intrinsic Value
Formycon AG engages in the manufacture of biosimilar drugs and formulations. [ Read More ]
The intrinsic value of one FYB stock under the Base Case scenario is 53.88 EUR. Compared to the current market price of 43.25 EUR, Formycon AG is Undervalued by 20%.
Valuation Backtest
Formycon AG
Run backtest to discover the historical profit from buying and selling FYB stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
Formycon AG
Current Assets | 67.1m |
Cash & Short-Term Investments | 27m |
Receivables | 28.3m |
Other Current Assets | 11.8m |
Non-Current Assets | 823.2m |
Long-Term Investments | 258m |
PP&E | 12.3m |
Intangibles | 552.9m |
Current Liabilities | 69.3m |
Accounts Payable | 16.3m |
Other Current Liabilities | 53m |
Non-Current Liabilities | 318.3m |
Long-Term Debt | 7.8m |
Other Non-Current Liabilities | 310.5m |
Earnings Waterfall
Formycon AG
Revenue
|
77.7m
EUR
|
Cost of Revenue
|
-54.8m
EUR
|
Gross Profit
|
22.9m
EUR
|
Operating Expenses
|
-23.3m
EUR
|
Operating Income
|
-369k
EUR
|
Other Expenses
|
76.2m
EUR
|
Net Income
|
75.8m
EUR
|
Free Cash Flow Analysis
Formycon AG
FYB Profitability Score
Profitability Due Diligence
Formycon AG's profitability score is 47/100. The higher the profitability score, the more profitable the company is.
Score
Formycon AG's profitability score is 47/100. The higher the profitability score, the more profitable the company is.
FYB Solvency Score
Solvency Due Diligence
Formycon AG's solvency score is 64/100. The higher the solvency score, the more solvent the company is.
Score
Formycon AG's solvency score is 64/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
FYB Price Targets Summary
Formycon AG
According to Wall Street analysts, the average 1-year price target for FYB is 98.99 EUR with a low forecast of 81.81 EUR and a high forecast of 136.5 EUR.
Shareholder Return
FYB Price
Formycon AG
Average Annual Return | 32.12% |
Standard Deviation of Annual Returns | 46.39% |
Max Drawdown | -59% |
Market Capitalization | 687.9m EUR |
Shares Outstanding | 17 656 900 |
Percentage of Shares Shorted |
N/A
|
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Formycon AG engages in the manufacture of biosimilar drugs and formulations. The company is headquartered in Martinsried, Bayern and currently employs 159 full-time employees. The company went IPO on 2010-12-20. Its business activities are focused on the development and marketing of biopharmaceuticals that are similar to existing drugs, for which the patent protection is expiring. The firm focuses on treatments in the area of ophthalmology, immunology and other chronic diseases, covering all steps of biosimilar development process, from early-stage analysis of the originator drug to the preclinical and clinical testing phases, as well as the preparation of dossiers for marketing approval. Its biosimilar product pipeline consists of four candidates in pre-clinical and clinical testing phases, including FYB201, a biosimilar candidate for Lucentis; FYB202, a biosimilar candidate for Stelara; FYB203, a biosimilar candidate for Eylea, and FYB205.
Contact
IPO
Employees
Officers
The intrinsic value of one FYB stock under the Base Case scenario is 53.88 EUR.
Compared to the current market price of 43.25 EUR, Formycon AG is Undervalued by 20%.